Junshi Biotech (688180.SH): Treprilizumab was approved for marketing in Hong Kong. It is the first and only immunotherapy drug for nasopharyngeal cancer tumors

Zhitongcaijing · 10/15 09:17

Zhitong Finance App News, Junshi Biotech (688180.SH) announced that Topuaili Biopharmaceutical Hong Kong Co., Ltd., a wholly-owned subsidiary of the company, has obtained the “Drug/Product Registration Certificate” issued by the Hong Kong Pharmacy and Poison Administration (“PPB”), and treprilimab (Hong Kong, China trade name: LOQTORZI®) combined with cisplatin/gemcitabine as first-line treatment for adult patients with metastatic or recurrent advanced nasopharyngeal cancer, and as a monotherapy for the recurrence and non-recurrence of disease progression after treatment or treatment with previous platinum-containing treatments or metastatic nasopharyngeal cancer The marketing license application for adult patients has been approved by PPB, and treprilizumab became the first and only tumor immunotherapy for nasopharyngeal cancer in Hong Kong, China.

After approval, treprilizumab became the first and only immunotherapy drug for nasopharyngeal cancer in Hong Kong, China. It is conducive to further broadening the commercial layout of the company's products, enhancing the international influence of the company's products, and is expected to have a positive impact on the company's long-term business performance.